用三年的宽限期，掩盖一个世纪的结构性迟钝Three Years of Reprieve Masking a Century of Structural Inertia
一百零五年。从胰岛素发现到今天，人类在 1 型糖尿病面前的逻辑竟然一直停留在“缺什么补什么”的低级替代阶段。这次 Teplizumab 的获批被包装成“新纪元”，但剥开叙事看，它提供的仅仅是最多三年的延迟。这在医学上是突破，但在结构性暴力面前，这只是一次精准的“缓刑”。
按照加尔通的暴力三角，一个人本可以达到的健康状态（Potential）与其实际状态（Actual）之间的差额就是暴力。对于 1 型糖尿病患者，尤其是那些在童年和青少年期发病的个体，这种差额是 lifelong 的。现在，系统通过一种免疫疗法，把这个差额的爆发时间往后推了三年。这意味着，原本在 10 岁就必须面对终身管理压力、被剥夺部分发育自由的孩子，现在可以被允许在“正常”的状态下多活三年。
这种“好消息”最危险的地方在于它容易制造一种“问题正在被解决”的文化假象。当 Nice 谈论“纳税人价值”和“商业协议”时，他们实际上是在给这种昂贵的延迟定价。这种定价权掌握在药企 Sanofi 和政府手中，而真正的受害者——那些处于 stage 2 的高风险人群，依然在等待一个被定义为“公平且平等”的准入机制。在资源分配的 structural layer，只要准入机制依然是黑盒，那么这种医疗进步就依然是特权阶层的优先选项。
我们不应该庆祝这种“延迟”，而应该质问：为什么在基因组学和免疫学如此发达的今天，我们依然只能在“补丁”和“缓刑”之间打转？三年的自由时间是珍贵的，但如果它被用来消解人们对彻底治愈的紧迫感，那么这种进步本身就成了另一种文化层面的共谋。
One hundred and five years. From the discovery of insulin to today, the human approach to type 1 diabetes has remained stuck in a primitive logic of "replacement." The approval of Teplizumab is being packaged as a "new era," but stripped of its narrative, it offers nothing more than a delay of up to three years. In medicine, this is a breakthrough; in the face of structural violence, it is merely a calculated reprieve.
Applying Galtung's Violence Triangle, the gap between a person's potential state of health and their actual state is violence. For those with type 1 diabetes, especially children, this gap is lifelong. Now, the system uses immunotherapy to push the eruption of this gap back by three years. Children who would have faced the crushing demands of lifelong management at ten are now granted three more years of "normalcy."
The danger of this "good news" lies in its capacity to manufacture a cultural illusion that the problem is being solved. While Nice discusses "taxpayer value" and "commercial arrangements," they are essentially pricing this expensive delay. The pricing power resides with Sanofi and the government, while the actual victims—the high-risk stage 2 population—must still wait for an access mechanism that is claimed to be "fair and equitable." In the structural layer of resource distribution, as long as access remains a black box, this medical progress remains a privilege for the few.
We should not celebrate this "delay"; we should question why, in an age of advanced genomics and immunology, we are still oscillating between "patches" and "reprieves." Three years of freedom are precious, but if they serve to dissolve the urgency for a total cure, then this progress itself becomes another form of complicity at the cultural level.